Eni SpA vs GSK plc — how do they compare? Eni SpA trades at $55.61 (market cap $78.80B), while GSK plc trades at $50.58 (market cap $104.15B). The key difference: GSK plc is the larger of the two by market cap, and Eni SpA pays the higher dividend (4.45%). Which is the better fit depends on your goals.
| E | GSK | |
|---|---|---|
Market Cap | $78.80B | $104.15B |
Sector | Energy | Health |
52-Week High | $57.61 | $61.18 |
52-Week Low | $34.03 | $38.22 |
Enterprise Value | $104.11B | $124.56B |
Dividend Yield | 4.45% | 3.48% |
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $53.61, down 1.22% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. Recent Q2 2026 earnings missed estimates despite 21.5% revenue growth, while the company increased its share buyback program. Valuation ratios appear attractive with a P/E of 12.08 and P/S of 0.79. Cash flow from operations remains strong at $13.33 billion for 2025, supporting dividend payments and strategic investments.
The outlook for Eni is cautiously optimistic, driven by production growth and strategic partnerships, but faces risks from commodity price volatility and geopolitical factors. Analyst consensus is mixed with 34.62% buy ratings, highlighting potential upside if operational execution improves and energy markets stabilize.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →